Ganglioside GM1 mimicry in Campylobacter strains from sporadic infections in the United States

Journal of Infectious Diseases

Volumn 179, Issue 5, 1999, Pages 1183-1189

  Nachamkin, Irving ^a,b,c,d,e   Ung, Huong ^a,b,c,d   Moran, Anthony P ^a,b,c,d   Yoo, Dale ^a,b,c,d   Prendergast, Martina M ^a,b,c,d   Nicholson, Mabel A ^a,b,c,d   Sheikh, Kazim ^a,b,c,d   Ho, Tony ^a,b,c,d   Asbury, Arthur K ^a,b,c,d   McKhann, Guy M ^a,b,c,d   Griffin, John W ^a,b,c,d  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b NATIONAL UNIVERSITY OF IRELAND   (Ireland)

^c CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^d JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPITOPE; GANGLIOSIDE GM1;

ARTICLE; BACTERIUM ISOLATE; CAMPYLOBACTER JEJUNI; CONTROLLED STUDY; ENTERITIS; GUILLAIN BARRE SYNDROME; MOLECULAR MIMICRY; NONHUMAN; PRIORITY JOURNAL; SEROTYPING; UNITED STATES;

CAMPYLOBACTER INFECTIONS; CAMPYLOBACTER JEJUNI; CHOLERA TOXIN; CHROMATOGRAPHY, THIN LAYER; DIARRHEA; EPITOPES; G(M1) GANGLIOSIDE; HUMANS; LIPOPOLYSACCHARIDES; MOLECULAR MIMICRY; POLYRADICULONEUROPATHY; SEROTYPING; UNITED STATES;

EID: 0032971176     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/314725     Document Type: Article

References (59)

1. 1. Tauxe RV. Epidemiology of Campylobacter jejuni infections in the United States and other industrialized nations. In: Campylobacter jejuni: current status and future trends. Nachamkin I, Blaser MJ, Tompkins LS, eds. Washington, DC: American Society for Microbiology, 1992:9-19.
2. 2. Ho TW, McKhann GM, Griffin JW. Human autoimmune neuropathies. Annu Rev Neurosci 1998:21:187-226.
3. 3. Hughes RAC, Rees JH. Clinical and epidemiologic features of Guillain-Barré syndrome. J Infect Dis 1997; 176(Suppl 2):92-8.
4. 4. Asbury AK, Arnason BG, Adams RD. The inflammatory lesion in idiopathic polyneuritis. Medicine 1969:48:173-215.
5. 5. Haymaker W, Kernohan JW. The Landry-Guillain-Barré syndrome. A clinicopathologic report of fifty fatal cases and a critique of the literature. Medicine 1949;28:59-141.
6. 6. Prineas JW. Acute idiopalhic polyneuritis. An electron microscope study. Lab Invest 1972;26:133-47.
7. 7. Griffin JW, Li CY, Ho TW, et al. Guillain-Barré syndrome in northern China: the spectrum of neuropathologic changes in clinically defined cases. Brain 1995;118:577-95.
8. 8. Ho TW, Mishu B, Li CY, et al. Guillain-Barré syndrome in northern China: relationship to Campylobacter jejuni infection and anti-glycolipid antibodies. Brain 1995;118:597-605.
9. 9. McKhann GM, Cornblath DR, Griffin JW, et al. Acute motor axonal neuropathy: a frequent cause of acute flaccid paralysis in China. Ann Neurol 1993;33:333-42.
10. 10. Ramos-Alvarez M, Bessudo L, Sabin A. Paralytic syndromes associated with noninflammatory cytoplasmic or nuclear neuronopathy: acute paralytic disease in Mexican children, neuropathologically distinguishable from Landry-Guillain-Barré syndrome. JAMA 1969;207:1481-92.
11. 11. Sobue G, Li M, Terao S, et al. Axonal pathology in Japanese Guillain-Barré syndrome: a study of 15 autopsied cases. Neurology 1997;48:1694-700.
12. 12. Griffin JW, Li CY, Macko C, et al. Early nodal changes in the acute motor axonal neuropathy pattern of the Guillain-Barré syndrome. J Neurocytol 1996;25:33-51.
13. 13. Hafer-Macko C, Hsieh ST, Li CY, et al. Acute motor axonal neuropathy: an antibody-mediated attack on axolemma. Ann Neurol 1996;40:635-44.
14. 14. Yuki N, Taki T, Inagaki F, et al. A bacterium lipopolysaccharide that elicits Guillain-Barré syndrome has a GM1 ganglioside structure. J Exp Med 1993;178:1771-5.
15. 15. Moran AP. Structure and conserved characteristics of Campylobacter jejuni lipopolysaccharides. J Infect Dis 1997; 176(Suppl 2):S1I5-21.
16. 16. Moran AP, Appelmelk BJ, Aspinall GO. Molecular mimicry of host structures by lipopolysaccharides of Campylobacter and Helicobacter spp: implications in pathogenesis. J Endotoxin Res 1996;3.521-31.
17. 17. Penner JL, Hennessy JN. Passive hemagglutination technique for serotyping Campylobacter fetus subsp jejuni on the basis of soluble heat-stable antigens. J Clin Microbiol 1980;12:732-7.
18. 18. Nachamkin I, Allos BM, Ho TW. Campylobacter and Guillain-Barré Syndrome. Clin Microbiol Rev 1998;11:555-67.
19. 19. Kuroki S, Saida T, Nukina M, et al. Campylobacter jejuni strains from patients with Guillain-Barré syndrome belong mostly to Penner serogroup 19 and contain B-N-acetylglucosamine residues. Ann Neurol 1993;33:243-7.
20. 20. Yuki N, Takahashi M, Tagawa Y, Kashiwase K, Tadokoro K, Saito K. Association of Campylobacter jejuni serotype and antiganglioside antibody in Guillain-Barré syndrome and Fisher's syndrome. Ann Neurol 1997;42: 28-33.
21. 21. Rees JH, Soudain SE, Gregson NA, Hughes RAC. Campylobacter jejuni infection and Guillain-Barré syndrome. N Engl J Med 1995;333:1374-9.
22. 22. Buzby JC, Allos BM, Roberts T. The economic burden of Campylobacter-associated Guillain-Barré syndrome. J Infect Dis 1997;176(Suppl 2): S192-7.
23. 23. Patton CM, Nicholson MA, Ostroff SM, Ries AA, Wachsmuth IK, Tauxe RV. Common somatic O and heat-labile serotypes among Campylobacter strains from sporadic infections in the United States. J Clin Microbiol 1993;31:1525-30.
24. 24. Spangler BD. Structure and function of cholera toxin and the related Escherichia coli heat-labile enterotoxin. Microbiol Rev 1992;56:622-47.
25. 25. Nachamkin I, Ung H, and Patton CM. Analysis of HL and O serotypes of Campylobacter strains by the flagellin gene typing system. J Clin Microbiol 1996;34:277-81.
26. 26. Aspinall GO, McDonald AG, Pang H. Lipopolysaccharides of Campylobacter jejuni serotype O:19: structures of O antigen chains from the serostrain and two bacterial isolates from patients with Guillain-Barré syndrome. Biochemistry 1994;33:250-5.
27. 27. Salloway S, Mermel LA, Seamans M, et al. Miller-Fisher syndrome associated with Campylobacter jejuni bearing lipopolysaccharide molecules that mimic human ganglioside GD3. Infect Immun 1996;64:2945-9.
28. 28. Moran AP, Rietschel ET, Kosunen TU, Zahringer U. Chemical characterization of Campylobacter jejuni lipopolysaccharides containing N-acetylneuraminic acid and 2,3-diamino-2,3-dideoxy-D-glucose. J Bacteriol 1991;173:618-26.
29. 29. Nachamkin I. Campylobacter and Arcobacter. In: Manual of Clinical Microbiology, Murray PR, Baron EJ, Pfaller MA, Tenover FC, Yolken RH, eds. Washington, DC: American Society for Microbiology Press, 1995: 483-91.
30. 30. Sheikh KA, Nachamkin I, Ho TW, et al. Campylobacter jejuni lipopolysac-charides in Guillain-Barré syndrome: molecular mimicry and host sus-ceptibility. Neurology 1998;51:371-8.
31. 31. Mills SD, Kurjanczyk LA, Penner JL. Antigenicity of Helicobacter pylori lipopolysaccharides. J Clin Microbiol 1992;30:3175-80.
32. 32. Schwerer B, Neisser A, Polk RJ, Bernheimer H, Moran AP. Antibody crossreactivities between gangliosides and lipopolysaccharides of Campylobacter jejuni serotypes associated with Guillain-Barré syndrome. J Endotoxin Res 1995;2:395-403.
33. 33. Prendergast MM, Lastovica AJ, Moran AP. Lipopolysaccharides from Campylobacter jejuni O:41 strains associated with Guillain-Barré syndrome exhibit mimicry of GM1 ganglioside. Infect Immun 1998;66:3649-55.
34. 34. Aspinall GO, Lynch CM, Pang H, Shaver RT, Moran AP. Chemical structures of the core region of Campylobacter jejuni O:3 lipopolysaccharide and an associated polysaccharide. Eur J Biochem 1995;231:570-8.
35. 35. Rhodes KM, Tattersfield AE. Guillain-Barré syndrome associated with Campylobacter infection. Br Med J (Clin Res Ed) 1982;285:173-4.
36. 36. Mishu B, IIyas AA, Koski CL, et al. Serologic evidence of previous Campylobacter jejuni infection in patients with Guillain-Barré syndrome. Ann Intern Med 1993;118:947-53.
37. 37. Aspinall GO, McDonald AG, Raju TS, et al. Chemical structure of the core region of Campylobacter jejuni serotype O:2 lipopolysaccharide. Eur J Biochem 1993;213:1029-37.
38. 38. Aspinall GO, McDonald AG, Raju TS, Pang H, Molan AP, Penner JL. Chemical structures of the core regions of Campylobacter jejuni serotypes O:1, O:4, O:23, and O:36 lipopolysaccharides. Eur J Biochem 1993;213: 1017-27.
39. 39. Aspinall GO, Fujimoto S, McDonald AG, Pang H, Kurjanczyk LA, Penner JL. Lipopolysaccharidcs from Campylobacter jejuni associated with Guillain-Barré syndrome patients mimic human gangliosides in structure. Infect Immun 1994;62:2122-5.
40. 40. Aspinall GO, McDonald AG, Pang H, Kurjanczyk LA, Penner JL. Lipopolysaccharides of Campylobacter jejuni serotype O:19: ssructures of core oligosaccharide regions from the serostrain and two bacterial isolates from patients with the Guillain-Barré syndrome. Biochemistry 1994;33:241-9.
41. 41. Yuki N, Taki T, Takahashi M, et al. Molecular mimicry between GQ1b ganglioside and lipopolysaccharides of Campylobacter jejuni isolated from patients with Fishers syndrome. Ann Neurol 1994;36:791-3.
42. 42. Ho TW, Willison H, Nachamkin I, et al. Anti-GD1a antibody distinguishes axonal from demyelinating forms of Guillain-Barré syndrome. Ann Neurol 1999;45:168-73.
43. 43. Lugaresi A, Ragno M, Torrieri F, DiGuglielmo G, Fermani P, Uncini A. Acute motor axonal neuropathy with high tiler IgG and IgA anti-GD1a antibodies following Campylobacter enteritis. J Neurol Sci 1997;147: 193-200.
44. 44. Yuki N, Yoshino H, Sato S, Shinozawa K, Miyatake T. Severe acute axonal form of Guillain-Barré syndrome associated with IgG anti-GD1a antibodies. Muscle Nerve 1992;15:899-903.
45. 45. Langmuir AD, Bregman DJ, Kurland LT, Nathanson N, Victor M. An epidemiologic and clinical evaluation of Guillain-Barré syndrome reported in association with the administration of swine influenza vaccines. Am J Epidemiol 1984;119:841-79.
46. 46. Moran AP, O'Malley DT. Potential role of lipopolysaccharides of Campylobacter jejuni in the development of Guillain-Barré syndrome. J Endoloxin Res 1995;2:233-5.
47. 47. Yuki N, Taki T, Takahashi M, et al. Penner's serogroup 4 of Campylobacter jejuni has a lipolpolysaccharide that bears a GM1 ganglioside epitope as well as one that bears a GD1a epitope. Infect Immun 1994;62:2101-3.
48. 48. Nishimura M, Nukina M, Kuroki S, et al. Characterization of Campylobacter jejuni isolates from patients with Guillain-Barré syndrome. J Neurol Sci 1997;153:91-9.
49. 49. Sack DA, Lastovica AJ, Chang SH, Pazzaglia G. Microtiter assay for detecting Campylobacter spp. and Helicobacter pylori with surface ganghosides which bind cholera toxin. J Clin Microbiol 1998;36:2043-5.
50. 50. Gregson NA, Rees JH, Hughes RAC. Reactivity of serum IgG anti-GM1 ganglioside antibodies with the lipopolysaccharide fractions of Campylobacter jejuni isolates from patients with Guillain-Barré syndrome (GBS). J Neuroimmunol 1997;73:28-36.
51. 51. Neisser A, Bernheimer H, Berger T, Moran AP, Schwerer B. Serum antibodies against gangliosides and Campylobacter jejuni lipopolysaccharides in Miller-Fisher syndrome. Infect Immun 1997;65:4038-42.
52. 52. Lastovica AJ, Goddard EA, Argent AC. Guillain-Barré syndrome in South Africa associated with Campylobacter jejuni O:41 strains. Clin Infect Dis 1997; 176(Suppl 2):S139-43.
53. 53. Penner JL, Aspinall GO. Diversity of lipopolysaccharide structures in Campylobacter jejuni. J Infect Dis 1997; 176(Suppl 2):S135-8.
54. 54. Li CY, Xue P, Gao CY, Tian WQ, Liu RC, Yang C. Experimental Campylobacter jejuni infection in the chicken: an animal model of axonal Guillain-Barré syndrome. J Neurol Neurosurg Psychiatry 1996; 61:279-84.
55. 55. Vriesendorp F. J Insights into Campylobacter jejuni inducted Guillain-Barré syndrome from the Lewis rat model of experimental allergic neuritis. J Infect Dis 1997; 176(Suppl 2):164-8.
56. 56. Rees JH, Vaughan RW, Kondeatis E, Hughes RAC. HLA-class II alleles in Guillain-Barré syndrome and Miller Fisher syndrome and their associá tion with preceding Campylobacter jejuni infection. J Neuroimmunol 1995;62:53-7.
57. 57. Monos DS, Papaioakim M, Ho TW, Li CY, McKhann CM. Differential distribution of HLA alleles in two forms of Guillain-Barré syndrome. J Infect Dis 1997; 176(suppl):S180-2.
58. 58. Doyle MP, Jones DM. Kood-borne transmission and antibiotic resistance of Campylobacter jejuni. In: Campylobacter jejuni: current status and future trends. Nachamkin I, Blaser MJ, Tompkins LS, eds. Washington, DC: American Society for Microbiology, 1992:45-8.
59. 59. Nielsen EM, Engberg J, Madsen M. Distribution of serotypes of Campylobacter jejuni and C. coli from Danish patients, poultry, cattle and swine. FEMS Immunol Med Microbiol 1997;19:47-56.